Anxiety Pathophysiology
Classification and Types of Anxiety Disorders
Anxiety disorders comprise a spectrum of conditions characterized by excessive, irrational fear and dread that disrupt daily functioning. These disorders are broadly divided into acute anxiety conditions and chronic generalized conditions.
Acute Anxiety Disorders
Panic Disorder: Characterized by sudden, recurrent, and unexpected episodes of intense fear accompanied by severe physical and cognitive symptoms (panic attacks).
Phobic Disorder: Involves irrational, debilitating fear and avoidance of specific objects, activities, or situations.
Obsessive-Compulsive Disorder (OCD): Marked by intrusive, unwanted thoughts (obsessions) and repetitive behaviors or mental acts (compulsions) performed to alleviate the associated distress.
Chronic Anxiety Disorders
Generalized Anxiety Disorder (GAD): Characterized by persistent, excessive, and uncontrollable worry about a wide variety of everyday events and activities, persisting for months. Symptoms often include severe psychological tension, restlessness, hypervigilance, and insomnia.
Neurobiology and Subunit Architecture of the GABAA Receptor Channel
The receptor is an ionotropic ligand-gated chloride channel that serves as the major inhibitory neurotransmitter receptor in the central nervous system. It represents one of the most versatile drug-responsive molecular complexes in neuropharmacology.

Subunit Composition and Isoforms
Pentameric Complex: The receptor is composed of five transmembrane glycoprotein subunits arranged symmetrically around a central chloride ion pore ( pore).
Polypeptide Classes: Subunits are drawn from multiple polypeptide classes, including , , , , , , and .
Subunit Isoforms: Within these classes, multiple specific isoforms exist:
isoforms: , , , , ,
isoforms: , , ,
isoforms: , ,
Major Brain Isoform: The most prevalent receptor configuration in the central nervous system is composed of two subunits, two subunits, and one subunit ().
Monomeric Subunit Structure: Each monomeric subunit consists of four hydrophobic transmembrane domains (domains 1 through 4). Transmembrane domain 2 (domain 2) specifically forms the inner lining of the central chloride channel pore.

Receptor Binding Sites and Mechanisms
GABA Binding Site: Located at the interface between adjacent and subunits ( junction). Binding of endogenous GABA triggers opening of the central channel, allowing hyperpolarizing influx into the postsynaptic neuron.
Benzodiazepine Site (BZD Site): Formed within an extracellular pocket between adjacent and subunits ( junction). Allosteric binding at this site increases the frequency of chloride channel opening, strictly requiring the concurrent presence of GABA.
Barbiturate Binding Site: Located on distinct regions of the and subunits. Allosteric binding increases the duration of time that the channel stays open. Barbiturates enhance influx in both the presence and the absence of GABA.
Ethanol Binding Site: Located at a distinct, separate site on the receptor complex; allosterically increases chloride influx.
Benzodiazepines: Pharmacology, Pharmacokinetics, and Therapeutics
Benzodiazepines are widely prescribed anxiolytic and sedative-hypnotic agents that enhance central inhibitory neurotransmission.
Mechanism of Action
Bind selectively to the BZD allosteric site at the junction of and subunits on the receptor.
Increase the affinity of the receptor for GABA, leading to an increased frequency of chloride channel opening.
Channel opening occurs only in the presence of GABA (GABA-dependent mechanism).
The resulting intracellular influx of ions causes neuronal hyperpolarization, which inhibits the depolarizing, action-potential-generating effects of excitatory neurotransmitters.
Pharmacokinetic Profile
Absorption & Distribution: Rapidly and well absorbed from the gastrointestinal tract following oral administration. Possess high lipid solubility, allowing rapid penetration into the central nervous system. Significant variation in rate of absorption exists across individual compounds.
Metabolism: Undergo extensive hepatic biotransformation.
Phase I Reactions: Catalyzed by cytochrome P450 (CYP450) enzymes (primarily oxidation), generating multiple pharmacologically active intermediate metabolites.
Phase II Reactions: Glucuronide conjugation yielding inactive polar metabolites excreted via the kidneys into the urine.
Enterohepatic Cycling: Many compounds and active metabolites undergo enterohepatic recirculation, prolonging their elimination half-lives.

Biotransformation Pathways
Chlordiazepoxide: Metabolized to Desmethylchlordiazepoxide, then to Demoxepam, which is converted to Desmethyldiazepam. Desmethyldiazepam is converted to Oxazepam*, which undergoes glucuronide conjugation for urinary excretion.
Diazepam: Metabolized directly to Desmethyldiazepam* (a pathway shared by Prazepam and the prodrug Clorazepate). Desmethyldiazepam* is hydroxylated to Oxazepam*, followed by conjugation and excretion.
Alprazolam and Triazolam: Metabolized via Phase I oxidation to active -hydroxy metabolites*, which undergo subsequent conjugation.
Flurazepam: Converted to Hydroxyethyl-flurazepam* and Desalkyl-flurazepam*, both of which undergo conjugation.
Lorazepam: Directly undergoes Phase II glucuronide conjugation without requiring active Phase I intermediate steps, making it safer in patients with hepatic impairment.
Pharmacologic Effects and Indications
Dose-Dependent CNS Depression:
Low doses produce sedation and anxiolysis.
High doses produce hypnosis and anesthesia.
Anterograde Amnesia: Impairs memory acquisition during the duration of drug action, making them useful adjuncts during stressful medical, surgical, or dental procedures.
Clinical Indications:
Insomnia
Muscle spasms and spasticity
Anxiety disorders (including Generalized Anxiety Disorder and Panic Disorder)
Seizure disorders
Alcohol withdrawal and detoxification (specifically Chlordiazepoxide and Diazepam)
Long-Term Use Risks and Adverse Effects
Long-Term Complications: Physical dependence, severe withdrawal syndrome upon abrupt cessation, rebound anxiety, insomnia, and persistent headache.
Adverse Effects: Excessive CNS depression, motor incoordination, dizziness, cognitive impairment, degradation of psychomotor skills, and occasional paradoxical disinhibition (uncontrolled excitement or aggression).
Clinical Cautions: Patients must avoid driving or operating heavy machinery. Polydrug abuse (especially co-ingestion with alcohol or opioids) markedly increases life-threatening respiratory depression.
Benzodiazepine Specific Drug Highlights
Alprazolam (Xanax®): Possesses short-acting metabolites resulting in a medium overall duration of action; heavily utilized in panic disorder and acute anxiety.
Diazepam (Valium®): Generates long-acting active metabolites (Desmethyldiazepam, Temazepam, Oxazepam) providing a prolonged duration of action.
Triazolam: Extremely short-acting hypnotic; banned in the United Kingdom due to a high incidence of adverse psychiatric and behavioral reactions (e.g., amnesia, anxiety, psychosis).
Benzodiazepine Antagonist: Flumazenil
Mechanism: Specific, competitive antagonist at the BZD binding site on the receptor.
Trade Name: Romazicon®.
Clinical Utility: Used to reverse the central sedative and respiratory depressive effects of benzodiazepine overdose or post-procedural anesthesia recovery. Rarely used routinely and restricted primarily to intensive care unit (ICU) settings.
Adverse Effects & Risks: Cardiac arrhythmias, blurred vision, dizziness, and sudden precipitation of severe seizures (particularly in patients with chronic benzodiazepine physical dependence or concomitant tricyclic antidepressant overdose).
Barbiturates: Pharmacology, Pharmacokinetics, and Safety Profile
Barbiturates are older, non-selective CNS depressants with a narrow therapeutic index.
Mechanism of Action
Bind to distinct allosteric binding sites on the and subunits of the receptor-chloride channel.
Increase the duration of time that the chloride channel remains open when activated.
At higher concentrations, barbiturates directly increase influx in both the presence and the absence of GABA (GABA-independent mechanism).
Induce powerful neuronal hyperpolarization without exhibiting a plateau effect (no ceiling effect), producing a steep linear dose-response curve. High doses lead to fatal respiratory depression, coma, and death.
Pharmacokinetic Profile
Onset and duration of action are determined primarily by lipid solubility and the rate of metabolic inactivation.
Amobarbital, Pentobarbital, and Thiopental: Highly lipid-soluble compounds. Well absorbed from the GI tract, rapidly redistributed from the central nervous system into peripheral tissues (fat and muscle), and extensively transformed by hepatic metabolism.
Phenobarbital: A polar, less lipid-soluble molecule. Slowly absorbed and slowly redistributed, partly excreted unchanged by the kidneys, with a long elimination half-life and duration of action.
Pharmacological Effects and Toxicity
Sleep Architecture Impact: Causes significant suppression of both slow-wave sleep and REM sleep, leading to sleep disruption upon discontinuation.
Adverse Effects: Marked sedation, residual "hangover" effect, cognitive slowing, rapidly developing tolerance, physical dependence, high potential for drug abuse, and life-threatening withdrawal syndrome.
Warnings & Contraindications:
Absolute avoidance during pregnancy and in nursing mothers (excreted in breast milk).
Strict avoidance with alcohol or other central nervous system depressants.
Enzyme Induction: Potent inducers of hepatic cytochrome P450 enzymes, significantly accelerating the metabolism of co-administered drugs.
Contraindicated in Porphyria: Barbiturates induce -aminolevulinate synthase, the rate-limiting enzyme in porphyrin biosynthesis. This triggers toxic accumulation of porphyrins, precipitating severe neurological and cutaneous porphyric crises.
Clinical Uses
Amobarbital & Pentobarbital: Management of severe insomnia.
Phenobarbital (Luminal®): Treatment of seizure disorders (epilepsy).
Thiopental: Rapid intravenous induction of general anesthesia.
Comparative Safety Profile: Benzodiazepines vs. Barbiturates
The comparative safety profile between barbiturates and benzodiazepines is defined by their distinct dose-response dynamics on the central nervous system.

Dose-Response Dynamics
Drug A (Barbiturates): Demonstrates a steep, linear dose-response relationship. As dose increases, CNS depression continuously progresses from sedation hypnosis anesthesia coma death. Because barbiturates can open chloride channels independently of GABA, there is no ceiling effect, resulting in a low margin of safety and high mortality risk in overdose.
Drug B (Benzodiazepines): Demonstrates a non-linear dose-response curve that plateaus (flattens out) at higher doses. Because benzodiazepines strictly require endogenous GABA to facilitate channel opening, their maximum effect is capped by endogenous GABA levels (ceiling effect). Sedation progresses to hypnosis, but higher doses alone rarely induce deep anesthesia or fatal coma, giving them a significantly higher margin of safety.
Antihistamines as Sedative-Anxiolytic Agents
Certain first-generation antihistamines are utilized for their central sedative and anxiolytic properties.
Individual Agents
Diphenhydramine (Benadryl®)
Hydroxyzine: Available as Hydroxyzine salt (Atarax®) and Hydroxyzine pamoate salt (Vistaril®).
Mechanism and Pharmacodynamics
Act as competitive histamine receptor antagonists and muscarinic acetylcholine receptor antagonists.
Highly lipophilic agents that readily cross the blood-brain barrier into the CNS.
Clinical Indications: Management of mild insomnia, generalized anxiety disorders, and pre-procedural sedation.
Limitations: Sedative effects diminish over time due to the rapid development of pharmacological tolerance.
Non-Sedating Anxiolytics and Sympatholytics
Non-sedating anxiolytics and sympatholytics target specific neural pathways without producing general CNS depression, hypnotic effects, or abuse liability.
Buspirone (BuSpar®)
Mechanism of Action: Partial agonist at presynaptic and postsynaptic serotonin receptors.
Pharmacokinetics: Short elimination half-life of .
Onset of Action: Very slow onset requiring a delay of to achieve full therapeutic anxiolytic efficacy.
Indication: Chronic management of Generalized Anxiety Disorder (GAD).
Clinical Advantages: Does not cause sedation, cognitive impairment, anterograde amnesia, motor incoordination, tolerance, physical dependence, or withdrawal symptoms. Exhibits no abuse potential.
Adverse Effects: Dizziness, headache, nervousness.
Cautions & Contraindications: Acute closed-angle glaucoma, severe renal or hepatic impairment, and concurrent use with Monoamine Oxidase (MAO) inhibitors due to the risk of precipitating severe hypertensive crises.
Sympatholytic Agents
Propranolol (Inderal®):
Mechanism: Non-selective -adrenergic receptor antagonist ( and blocker).
Indication: Management of acute performance anxiety and "stage fright". Blocks peripheral sympathetic nervous system responses, effectively preventing somatic symptoms such as tachycardia, muscular tremors, and diaphoresis.
Prazosin (Minipress®):
Mechanism: Selective -adrenergic receptor antagonist.
Indication: Reduction of severe nightmares and sleep disruption associated with Post-Traumatic Stress Disorder (PTSD).
Comparative Pharmacokinetic Profiles and Clinical Uses
Pharmacokinetic parameters determine the specific clinical application of sedative-hypnotic and anxiolytic medications.
Parameter Definitions
Onset of Action Thresholds:
Very Fast:
Fast:
Slow:
Very Slow:
Duration of Action Thresholds:
Very Short:
Short:
Medium:
Long:
Pharmacokinetic Properties Table
Drug Class & Agent | Onset of Action | Duration of Action | Active Metabolites | Major Clinical Uses |
|---|---|---|---|---|
Benzodiazepines | ||||
Alprazolam | Fast | Medium | Yes | Anxiety, including panic disorder |
Chlordiazepoxide | Fast; Very Fast (IV) | Long | Yes | Alcohol detoxification; anxiety |
Clonazepam | Fast | Medium | No | Anxiety, including panic disorder; seizure disorders |
Diazepam | Fast; Very Fast (IV) | Long | Yes | Alcohol detoxification; anxiety; muscle spasm; seizure disorders; spasticity |
Estazolam | Fast | Medium | Yes | Insomnia |
Flurazepam | Fast | Long | Yes | Insomnia |
Lorazepam | Fast; Very Fast (IV) | Medium | No | Anxiety; seizure disorders |
Midazolam | Very Fast (IV) | Short (IV) | Yes | Anesthesia |
Oxazepam | Fast | Short | No | Anxiety |
Temazepam | Fast | Medium | No | Insomnia |
Triazolam | Fast | Short | Yes | Insomnia |
Barbiturates | ||||
Amobarbital | Fast | Medium | No | Insomnia |
Pentobarbital | Fast | Short | No | Insomnia |
Phenobarbital | Slow | Long | No | Seizure disorders |
Thiopental | Very Fast (IV) | Short (IV) | No | Induction of anesthesia |
Antihistamines | ||||
Diphenhydramine | Fast | Medium | No | Insomnia |
Hydroxyzine | Fast | Long | No | Anxiety; sedation |
Other Sedative-Hypnotics | ||||
Chloral Hydrate | Fast | Medium | Yes | Insomnia; preanesthetic sedation |
Melatonin | Fast | Medium | No | Insomnia, including jet lag |
Zaleplon | Fast | Very Short | No | Insomnia |
Zolpidem | Fast | Short | No | Insomnia |
Nonsedating Anxiolytics | ||||
Buspirone | Very Slow | Long | No | Chronic anxiety |
Propranolol | Fast | Medium | Yes | Situational or performance anxiety |
Practice Questions
Question 1
Which of the following medications act on the receptor only in the presence of GABA? (Select the two correct answers.)
A. Alprazolam
B. Amobarbital
C. Chlordiazepoxide
D. Thiopental
Answer: A and C. Explanation: Benzodiazepines such as Alprazolam and Chlordiazepoxide bind to the allosteric BZD site on the receptor and enhance chloride channel opening frequency exclusively in the presence of endogenous GABA. Barbiturates such as Amobarbital and Thiopental can open the chloride channel independently of GABA at higher concentrations.
Question 2
Which pharmacological effect best describes the mechanism of action of hydroxyzine?
A. antagonist
B. antagonist
C. antagonist
D. antagonist
Answer: D. Explanation: Hydroxyzine is a first-generation antihistamine that acts as a competitive histamine receptor antagonist (and muscarinic receptor antagonist) in the central nervous system to produce sedation and anxiolysis.